MCC
MCID: MRK001
MIFTS: 52

Merkel Cell Carcinoma (MCC) malady

Categories: Rare diseases, Skin diseases, Endocrine diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Merkel Cell Carcinoma

Aliases & Descriptions for Merkel Cell Carcinoma:

Name: Merkel Cell Carcinoma 12 50 56 14 69
Cutaneous Neuroendocrine Carcinoma 50 56
Trabecular Adenocarcinoma 12 69
Merkel Cell Cancer 50 29
Carcinoma, Merkel Cell 50
Carcinoma Merkel Cell 52
Trabecular Carcinoma 12
Merkle Tumors 50
Mcc 56

Characteristics:

Orphanet epidemiological data:

56
cutaneous neuroendocrine carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe),1-9/100000 (Australia); Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:3965
NCIt 47 C4068
SNOMED-CT 64 29792007
Orphanet 56 ORPHA79140
ICD10 via Orphanet 34 C44.6 C44.7 C44.3
UMLS 69 C0302182

Summaries for Merkel Cell Carcinoma

NIH Rare Diseases : 50 merkel cell carcinoma (mcc) is a rare, aggressive skin cancer. it usually develops as a single, painless, bump on sun-exposed skin. the bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. it may spread quickly to surrounding tissues, nearby lymph nodes, or more distant parts of the body. factors associated with developing mcc include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the merkel cell polyomavirus. this virus has been detected in about 80% of people with mcc. treatment may include surgery, radiation therapy, and/or chemotherapy. treatment options and prognosis depend on the location(s) and size of the cancer, whether it has just been diagnosed or has come back (recurred), and how deeply it has grown into the skin. last updated: 3/9/2017

MalaCards based summary : Merkel Cell Carcinoma, also known as cutaneous neuroendocrine carcinoma, is related to duodenal obstruction and allergic contact dermatitis. An important gene associated with Merkel Cell Carcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are NF-kappaB Signaling and Neuroscience. The drugs Anastrozole and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and thyroid, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 71 Merkel-cell carcinoma (MCC) is a rare and highly aggressive skin cancer, which, in most cases, is caused... more...

Related Diseases for Merkel Cell Carcinoma

Diseases related to Merkel Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
id Related Disease Score Top Affiliating Genes
1 duodenal obstruction 29.7 KRT8 NKX2-1 SYP
2 allergic contact dermatitis 29.7 KRT20 MUC1 NKX2-1 TP53
3 glomus tumor 29.7 ENO2 KIT NCAM1 SYP
4 differentiating neuroblastoma 29.6 ENO2 MAP2 MUC1
5 pheochromocytoma 29.5 CHGA ENO2 SST SYP
6 neuroblastoma 29.4 ENO2 KIT NCAM1 SYP TP53
7 penile cancer 11.0
8 peroneal nerve paralysis 10.3 CHGA SYP
9 brain stem ependymoma 10.3 CHGA SYP
10 infiltrating renal pelvis transitional cell carcinoma 10.3 ENO2 SYP
11 peritoneal benign neoplasm 10.3 CHGA KRT20
12 dystonia 10.3 CHGA KRT20
13 anal canal paget's disease 10.3 CHGA KRT20
14 extrahepatic biliary papillomatosis 10.3 CHGA SYP
15 sm-ahnmd 10.3 CHGA ENO2
16 villous adenocarcinoma 10.3 CHGA NKX2-1 SYP
17 myelinoclastic diffuse sclerosis 10.3 ENO2 MUC1
18 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
19 chromophil adenoma of the kidney 10.3 ENO2 KRT20 NKX2-1
20 cavernous hemangioma of face 10.3 CHGA NKX2-1 SYP
21 uterine corpus sarcoma 10.3 ENO2 NCAM1
22 cartilage cancer 10.3 CHGA SYP
23 thymus small cell carcinoma 10.3 CHGA ENO2 SYP
24 granulocytopenia 10.3 CHGA ENO2 KRT20
25 gliofibroma 10.3 CHGA ENO2 SYP
26 intrahepatic bile duct adenoma 10.2 NCAM1 SYP
27 thymic dysplasia 10.2 MUC1 NCAM1
28 microinvasive cervical squamous cell carcinoma 10.2 CHGA MUC1 SYP
29 paraphimosis 10.2 KRT20 SYP TP53
30 breast pericanalicular fibroadenoma 10.2 KRT20 NKX2-1 TP53
31 acute stress disorder 10.2 ENO2 KRT20 SYP
32 piussan lenaerts mathieu syndrome 10.2 CHGA ENO2 SYP
33 chondroblastoma 10.2 KRT20 MUC1 NKX2-1
34 jejunal neuroendocrine tumor 10.2 CHGA SYP
35 gastrointestinal system benign neoplasm 10.2 CHGA ENO2 NKX2-1
36 ampulla of vater mucinous adenocarcinoma 10.2 CHGA ENO2 SYP
37 skeletal-extraskeletal angiomatosis 10.2 ENO2 MUC1 SYP
38 kidney disease 10.2 NKX2-1 SYP TP53
39 bone deterioration disease 10.2 NKX2-1 SYP TP53
40 sebaceous adenoma 10.2 KIT MUC1 SYP
41 main bronchus cancer 10.2 CHGA NCAM1 SYP
42 thymoma 10.2 ENO2 MUC1 SYP
43 blood group incompatibility 10.2 ENO2 SYP TP53
44 colorectal cancer 1 10.2 CHGA ENO2 SYP
45 cavernous hemangioma of colon 10.2 ENO2 NCAM1
46 clitoris cancer 10.2 KRT20 MUC1
47 ovarian germ cell teratoma 10.2 KIT NCAM1 SYP
48 ampullary signet ring cell adenocarcinoma 10.2 ENO2 NCAM1 SYP
49 gallbladder pleomorphic giant cell adenocarcinoma 10.2 ENO2 SYP TP53
50 zollinger-ellison syndrome 10.2 CHGA ENO2 SYP

Graphical network of the top 20 diseases related to Merkel Cell Carcinoma:



Diseases related to Merkel Cell Carcinoma

Symptoms & Phenotypes for Merkel Cell Carcinoma

MGI Mouse Phenotypes related to Merkel Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 CD274 ENO2 KIT MAP2 NCAM1 NKX2-1
2 growth/size/body region MP:0005378 9.85 CHGA ENO2 KIT KRT8 MAP2 NKX2-1
3 mortality/aging MP:0010768 9.7 CD274 CHGA KIT KRT8 MAP2 NCAM1
4 nervous system MP:0003631 9.32 PAX5 PDGFRA SST SYP TP53 ENO2

Drugs & Therapeutics for Merkel Cell Carcinoma

Drugs for Merkel Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
2
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757 53477783
3
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
4 Antineoplastic Agents, Hormonal Phase 3,Phase 1
5 Hormone Antagonists Phase 3,Phase 1,Phase 2
6 Hormones Phase 3,Phase 1,Phase 2
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
8 Aromatase Inhibitors Phase 3
9 Estradiol 17 beta-cypionate Phase 3
10 Estradiol 3-benzoate Phase 3
11 Estradiol valerate Phase 3 979-32-8
12 Estrogen Antagonists Phase 3
13 Estrogen Receptor Antagonists Phase 3
14 Estrogens Phase 3
15 Polyestradiol phosphate Phase 3
16 Steroid Synthesis Inhibitors Phase 3
17
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
18
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
19
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
20
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
21
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
22
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
23
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
24
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
25
Somatostatin Approved Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605
26
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
27
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
29
nivolumab Approved Phase 2,Phase 1 946414-94-4
30
lanreotide Approved Phase 2 108736-35-2
31
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
32
Daratumumab Approved Phase 1, Phase 2 945721-28-8
33
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
34
Pancrelipase Approved Phase 2 53608-75-6
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
37
Etoposide Approved Phase 2 33419-42-0 36462
38
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
39
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 54575, 6560146 143
42
Camptothecin Experimental Phase 2 7689-03-4
43 Albumin-Bound Paclitaxel Phase 2,Phase 1
44 Analgesics Phase 2,Phase 1
45 Analgesics, Non-Narcotic Phase 2,Phase 1
46 Antibodies Phase 2,Phase 1
47 Antibodies, Monoclonal Phase 2,Phase 1
48 Antimitotic Agents Phase 2,Phase 1
49 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
50 Immunoglobulins Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 53)
id Name Status NCT ID Phase
1 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3
2 F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Unknown status NCT02054884 Phase 2
3 S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Completed NCT00003549 Phase 2
4 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Completed NCT01440816 Phase 2
5 Oblimersen in Treating Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
6 S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Completed NCT00068783 Phase 2
7 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Completed NCT00004922 Phase 2
8 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2
9 Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation Recruiting NCT02196961 Phase 2
10 Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Recruiting NCT02155647 Phase 2
11 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Recruiting NCT02514824 Phase 1, Phase 2
12 QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Recruiting NCT02465957 Phase 2
13 Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Recruiting NCT02584829 Phase 1, Phase 2
14 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting NCT02819843 Phase 2
15 Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Recruiting NCT03071406 Phase 2
16 Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Recruiting NCT02351128 Phase 2
17 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma Recruiting NCT02501473 Phase 1, Phase 2
18 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2
19 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2
20 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2
21 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03126110 Phase 1, Phase 2
22 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2
23 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Recruiting NCT03002623 Phase 2
24 Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Recruiting NCT02315625 Phase 2
25 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors Recruiting NCT01967537 Phase 2
26 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02036476 Phase 2
27 Merkel Positron Emission Tomography (PET) Protocol Active, not recruiting NCT01013779 Phase 2
28 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Active, not recruiting NCT02267603 Phase 2
29 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Active, not recruiting NCT01237457 Phase 2
30 QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Not yet recruiting NCT03167164 Phase 1, Phase 2
31 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Not yet recruiting NCT02978625 Phase 2
32 Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Terminated NCT01758458 Phase 1, Phase 2
33 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2
34 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2
35 A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel C Completed NCT01652547 Phase 1
36 BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00346385 Phase 1
37 Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System Completed NCT01172860 Phase 1
38 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
39 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1
40 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Recruiting NCT02890368 Phase 1
41 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03071757 Phase 1
42 A Study of ABBV-181 in Participants With Advanced Solid Tumors Recruiting NCT03000257 Phase 1
43 A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Active, not recruiting NCT02035657 Phase 1
44 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
46 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
47 The Impact of Total Body Skin Examination on Skin Cancer Detection Completed NCT00765193
48 Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Completed NCT01526486
49 Optical Biopsy of Human Skin in Conjunction With Laser Treatment Completed NCT00540566
50 Studies of Dermatologic Diseases Biospecimen Acquisition Protocol Recruiting NCT02471352

Search NIH Clinical Center for Merkel Cell Carcinoma

Genetic Tests for Merkel Cell Carcinoma

Genetic tests related to Merkel Cell Carcinoma:

id Genetic test Affiliating Genes
1 Merkel Cell Carcinoma 29

Anatomical Context for Merkel Cell Carcinoma

MalaCards organs/tissues related to Merkel Cell Carcinoma:

39
Skin, Lymph Node, Thyroid, Pancreas, Lung, Kidney, T Cells

Publications for Merkel Cell Carcinoma

Articles related to Merkel Cell Carcinoma:

(show top 50) (show all 761)
id Title Authors Year
1
A population-based cohort study of the influence of socioeconomic factors and race on survival in Merkel cell carcinoma. ( 27986144 )
2017
2
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. ( 28049147 )
2017
3
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. ( 27984768 )
2017
4
Skin ultrasound features of Merkel cell carcinoma. ( 28045198 )
2017
5
History of chronic inflammatory disorders increases the risk of Merkel cell carcinoma, but does not correlate with Merkel cell polyomavirus infection. ( 27978533 )
2017
6
Histological Features, p53, c-Kit, and Poliomavirus Status and Impact on Survival in Merkel Cell Carcinoma Patients. ( 27442046 )
2016
7
Complete Spontaneous Regression of Merkel Cell Carcinoma (1986-2016): A 30 year perspective. ( 27596690 )
2016
8
Comment on "merkel cell carcinoma in a vein graft donor site". ( 28040814 )
2016
9
RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells. ( 27121059 )
2016
10
Isolated limb perfusion in Merkel cell carcinoma offers high rate of complete response and durable local-regional control: Systematic review and institutional experience. ( 27189050 )
2016
11
Revisiting PAX-8's Labeling of Merkel Cell Carcinoma. ( 28002100 )
2016
12
Immunotherapy: Overcoming checkpoints in Merkel-cell carcinoma. ( 27141888 )
2016
13
Squamous Cell Carcinoma In Situ Overlying Merkel Cell Carcinoma. ( 27207346 )
2016
14
Intraepidermal Merkel cell carcinoma with pagetoid Bowen's disease. ( 27758029 )
2016
15
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. ( 27592805 )
2016
16
Epidemiological trends in Merkel cell carcinoma in southern France: a registry-based study. ( 27515470 )
2016
17
Rapidly Fatal Dissemination of Merkel Cell Carcinoma in a Patient Treated with Alemtuzumab for Chronic Lymphocytic Leukemia. ( 27509643 )
2016
18
A Case of Nasal Merkel Cell Carcinoma Draining to a Buccinator Sentinel Lymph Node. ( 27607170 )
2016
19
Metastatic Merkel cell carcinoma response to nivolumab. ( 27879975 )
2016
20
Mohs Micrographic Surgery for the Treatment of Merkel Cell Carcinoma. ( 27467228 )
2016
21
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. ( 26655088 )
2016
22
Sentinel lymph node biopsy and survival in Merkel cell carcinoma: A 10 year review. ( 27544843 )
2016
23
Merkel Cell Carcinoma of the Eyelid. ( 27664912 )
2016
24
Metabolic assessment of Merkel cell carcinoma: the role of 18F-FDG PET/CT. ( 27092665 )
2016
25
TTF-1 and PAX5 Are Frequently Expressed in Combined Merkel Cell Carcinoma. ( 27322785 )
2016
26
Left-sided laterality of Merkel cell carcinoma in a German population: more than just sun exposure. ( 27778198 )
2016
27
Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. ( 27815175 )
2016
28
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. ( 27177440 )
2016
29
Merkel cell polyomavirus infection and Merkel cell carcinoma. ( 27521569 )
2016
30
Merkel Cell Carcinoma: rising incidence in the East of England. ( 27515234 )
2016
31
Secondary Merkel Cell Carcinoma Arising From a Graft Donor Site. ( 27777334 )
2016
32
A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study. ( 27544490 )
2016
33
Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. ( 26902929 )
2016
34
Merkel cell carcinoma: a review. ( 27163912 )
2016
35
Parotid gland metastasis in Merkel cell carcinoma of the head and neck: A series of 14 cases. ( 27657318 )
2016
36
Eyelid Merkel Cell Carcinoma. ( 27549876 )
2016
37
Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. ( 27198511 )
2016
38
Prognostic relevance of high atonal homolog-1 expression in Merkel cell carcinoma. ( 27624714 )
2016
39
A pilot study of SPECT/CT-based mixed-reality navigation towards the sentinel node in patients with melanoma or Merkel cell carcinoma of a lower extremity. ( 27076206 )
2016
40
Merkel Cell Carcinoma: An Update of Key Imaging Techniques, Prognostic Factors, Treatment, and Follow-up. ( 27919405 )
2016
41
ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. ( 26827764 )
2016
42
Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis. ( 27856777 )
2016
43
Metastatic Merkel cell carcinoma of the face. ( 27212280 )
2016
44
Merkel cell carcinoma associated with stable chronic hemodialysis: A report of two cases. ( 27334898 )
2016
45
Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma. ( 26877261 )
2016
46
Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. ( 27166398 )
2016
47
Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma. ( 27122984 )
2016
48
Cytokeratin-positive fibroblastic reticular cell: a pitfall for dermatopathologists assessing lymph nodes for Merkel cell carcinoma. ( 27640340 )
2016
49
Pembrolizumab Yields Lasting Merkel Cell Carcinoma Responses. ( 27099233 )
2016
50
Serological biomarkers for determining prognosis in Merkel cell carcinoma. ( 27115583 )
2016

Variations for Merkel Cell Carcinoma

Cosmic variations for Merkel Cell Carcinoma:

9 (show all 15)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 19
2 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 19
3 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 19
4 COSM214151 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.585G>A p.W195* 19
5 COSM1731707 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.1789C>T p.Q597* 19
6 COSM1735721 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.297G>A p.W99* 19
7 COSM1735722 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.298G>A p.G100R 19
8 COSM5316 PTEN skin,NS,carcinoma,Merkel cell carcinoma c.439A>T p.K147* 19
9 COSM249774 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.56G>A p.R19K 19
10 COSM760 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1624G>A p.E542K 19
11 COSM27133 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>C p.E545Q 19
12 COSM766 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1636C>A p.Q546K 19
13 COSM776 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.3140A>T p.H1047L 19
14 COSM29052 PTCH1 skin,back,carcinoma,NS c.724C>T p.Q242* 16
15 COSM763 PIK3CA skin,back,carcinoma,NS c.1633G>A p.E545K 16

Copy number variations for Merkel Cell Carcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32219 1 34600000 44100000 Amplification MYCL1 Merkel cell carcinoma
2 77110 13 40100000 73300000 Deletion Merkel cell carcinoma
3 200959 5 63200000 102800000 Deletion Merkel cell carcinoma

Expression for Merkel Cell Carcinoma

Search GEO for disease gene expression data for Merkel Cell Carcinoma.

Pathways for Merkel Cell Carcinoma

Pathways related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.12 CD274 KIT NCAM1 PAX5
2 11.86 ENO2 MAP2 NCAM1 NKX2-1 SYP
3 11.25 KIT PDGFRA TP53
4 11.06 KIT NCAM1 PDGFRA
5 10.83 MAP2 NCAM1 PDGFRA SYP

GO Terms for Merkel Cell Carcinoma

Cellular components related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD274 KIT NCAM1 PDGFRA

Biological processes related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-mediated signaling GO:0048015 9.58 KIT PDGFRA TP53
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
3 mast cell degranulation GO:0043303 9.32 CHGA KIT
4 Leydig cell differentiation GO:0033327 9.26 NKX2-1 PDGFRA
5 positive regulation of phospholipase C activity GO:0010863 9.16 KIT PDGFRA
6 mast cell chemotaxis GO:0002551 8.96 CHGA KIT
7 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Molecular functions related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.8 KIT NCAM1 PDGFRA

Sources for Merkel Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....